The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.
<h4>Background</h4>Toripalimab, a monoclonal antibody designed to target PD-1, has recently received approval from the U.S. Food and Drug Administration (FDA) for use as a first-line treatment in adults diagnosed with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0326216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473384164884480 |
|---|---|
| author | Qian Guo Dong Dong Zihan Dang Shuman Huang Xinjie Qiao Baiquan Zhang Yulin Zhao |
| author_facet | Qian Guo Dong Dong Zihan Dang Shuman Huang Xinjie Qiao Baiquan Zhang Yulin Zhao |
| author_sort | Qian Guo |
| collection | DOAJ |
| description | <h4>Background</h4>Toripalimab, a monoclonal antibody designed to target PD-1, has recently received approval from the U.S. Food and Drug Administration (FDA) for use as a first-line treatment in adults diagnosed with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). The purpose of this study is to utilize the FAERS database and bibliometric analysis to examine adverse events associated with toripalimab in real-world settings, thereby enhancing the safety management of clinical medications.<h4>Methods</h4>This research implemented a disproportionality analysis to assess the safety of toripalimab by reviewing all adverse event reports from the FAERS database dating back to 2004, wherein toripalimab was recognized as the main suspected medication. Various statistical techniques were applied in the analysis, such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN), to evaluate the adverse events linked to toripalimab. CiteSpace is utilized to search for authors, countries, keywords, and various indicators within research fields, facilitating the identification of research hotspots and future trends.<h4>Results</h4>From 2004 to 2024, 441 AEs linked to toripalimab were recorded across 27 SOCs. The top five SOCs were procedural complications, investigations, blood/lymphatic disorders, gastrointestinal disorders, and skin/subcutaneous disorders. At the PT level, the top five AEs by ROR were myelosuppression (n = 192, ROR 687.41), decreased granulocyte count (n = 11, ROR 515.72), immune-mediated hepatic disorder (n = 7, ROR 343.20), immune-mediated myocarditis (n = 3, ROR 214.68), and bicytopenia (n = 3, ROR 117.49). Additionally, 91.62% of AEs occurred within the first 30 days, and immune-related AEs were highlighted in bibliometric analysis.<h4>Conclusion</h4>This research provides initial safety information regarding the real-world application of toripalimab, affirming previously acknowledged adverse effects and concurrently uncovering new possible risks. These results could act as important cautionary evidence for healthcare professionals and pharmacists engaged in administering toripalimab for NPC. |
| format | Article |
| id | doaj-art-bd45e235fbd440bb85baa59b4a3b9f90 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-bd45e235fbd440bb85baa59b4a3b9f902025-08-20T03:24:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01206e032621610.1371/journal.pone.0326216The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.Qian GuoDong DongZihan DangShuman HuangXinjie QiaoBaiquan ZhangYulin Zhao<h4>Background</h4>Toripalimab, a monoclonal antibody designed to target PD-1, has recently received approval from the U.S. Food and Drug Administration (FDA) for use as a first-line treatment in adults diagnosed with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). The purpose of this study is to utilize the FAERS database and bibliometric analysis to examine adverse events associated with toripalimab in real-world settings, thereby enhancing the safety management of clinical medications.<h4>Methods</h4>This research implemented a disproportionality analysis to assess the safety of toripalimab by reviewing all adverse event reports from the FAERS database dating back to 2004, wherein toripalimab was recognized as the main suspected medication. Various statistical techniques were applied in the analysis, such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN), to evaluate the adverse events linked to toripalimab. CiteSpace is utilized to search for authors, countries, keywords, and various indicators within research fields, facilitating the identification of research hotspots and future trends.<h4>Results</h4>From 2004 to 2024, 441 AEs linked to toripalimab were recorded across 27 SOCs. The top five SOCs were procedural complications, investigations, blood/lymphatic disorders, gastrointestinal disorders, and skin/subcutaneous disorders. At the PT level, the top five AEs by ROR were myelosuppression (n = 192, ROR 687.41), decreased granulocyte count (n = 11, ROR 515.72), immune-mediated hepatic disorder (n = 7, ROR 343.20), immune-mediated myocarditis (n = 3, ROR 214.68), and bicytopenia (n = 3, ROR 117.49). Additionally, 91.62% of AEs occurred within the first 30 days, and immune-related AEs were highlighted in bibliometric analysis.<h4>Conclusion</h4>This research provides initial safety information regarding the real-world application of toripalimab, affirming previously acknowledged adverse effects and concurrently uncovering new possible risks. These results could act as important cautionary evidence for healthcare professionals and pharmacists engaged in administering toripalimab for NPC.https://doi.org/10.1371/journal.pone.0326216 |
| spellingShingle | Qian Guo Dong Dong Zihan Dang Shuman Huang Xinjie Qiao Baiquan Zhang Yulin Zhao The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis. PLoS ONE |
| title | The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis. |
| title_full | The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis. |
| title_fullStr | The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis. |
| title_full_unstemmed | The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis. |
| title_short | The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis. |
| title_sort | adverse events of toripalimab in nasopharyngeal carcinoma based on faers database and bibliometric analysis |
| url | https://doi.org/10.1371/journal.pone.0326216 |
| work_keys_str_mv | AT qianguo theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT dongdong theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT zihandang theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT shumanhuang theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT xinjieqiao theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT baiquanzhang theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT yulinzhao theadverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT qianguo adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT dongdong adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT zihandang adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT shumanhuang adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT xinjieqiao adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT baiquanzhang adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis AT yulinzhao adverseeventsoftoripalimabinnasopharyngealcarcinomabasedonfaersdatabaseandbibliometricanalysis |